Catabasis Pharma (CATB) Tops Q2 EPS by 3c

Catabasis Pharma (NASDAQ: CATB) reported Q2 EPS of ($0.20), $0.03 better than the analyst estimate of ($0.23).

“We are thrilled to have achieved important milestones that enable the Phase 3 PolarisDMD trial of edasalonexent for registration purposes. We are now completing final preparations and expect to initiate the Phase 3 trial in the coming months,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “Based on muscle effects and stabilization of function seen with edasalonexent treatment in Phase 2, we believe edasalonexent could fundamentally change the course of Duchenne disease progression and the treatment paradigm. We look forward to advancing edasalonexent into the PolarisDMD trial as we progress towards our goal of making edasalonexent available to all those affected by Duchenne with the hope of enabling patients to maintain their functional abilities longer.”

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Reading (RDI) Tops Q2 EPS by 4c